Combined Intervention Program for Non-fluent Aphasia Based on Neuroplasticity

Browse trials for

• Aphasia, Broca 35
• Stroke 8,255

Keywords

• Non-fluent aphasia
• Neuroplasticity
• Melodic Intonation Therapy
• Constraint-Induced Aphasia Therapy
• Subacute phase
• Chronic phase
• Stroke

Aphasia, Broca

35 studies on the registry are indexed under Aphasia, Broca; 11 are open to participants now.

This study's planned enrollment of 48 is above the median of 36 across 33 interventional studies indexed under Aphasia, Broca.

Lead sponsor

Universidad de Granada is the lead sponsor of 246 studies on the registry; 43 are open to participants now.

Study arms

• Experimental
  Experimental group

  CIPAN = MIT + CIAT

  Behavioral: CIPAN = MIT + CIAT

• Active comparator
  Control group 1

  MIT + MIT

  Behavioral: MIT + MIT

• Active comparator
  Control group 2

  CIAT + CIAT

  Behavioral: CIAT + CIAT

Interventions

• BehavioralCIPAN = MIT + CIAT

  The First Therapeutic Period (1st TP) takes place during the subacute phase, from 10 to 15 weeks since the patient's stroke onset. The Second Therapeutic Period (2nd TP) occurs during the chronic phase, from 27 to 32 weeks since the patient's stroke onset. MIT sessions (1st TP) will last one hours each and will be administered daily (5 days per week) over six weeks, amounting to a total of 30 hours of therapy. CIAT sessions (2nd TP) will be three-hour long and delivered on a daily basis (also 5 days per week) for two weeks, resulting in a total of 30 hours of therapy.

• BehavioralMIT + MIT

  The First Therapeutic Period (1st TP) takes place during the subacute phase, from 10 to 15 weeks since the patient's stroke onset. The Second Therapeutic Period (2nd TP) occurs during the chronic phase, from 27 to 32 weeks since the patient's stroke onset. MIT sessions (1st TP) will last one hours each and will be administered daily (5 days per week) over six weeks, amounting to a total of 30 hours of therapy. MIT sessions (2nd TP) will last one hours each and will be administered daily (5 days per week) over six weeks, amounting to a total of 30 hours of therapy.

• BehavioralCIAT + CIAT

  The First Therapeutic Period (1st TP) takes place during the subacute phase, from 10 to 15 weeks since the patient's stroke onset. The Second Therapeutic Period (2nd TP) occurs during the chronic phase, from 27 to 32 weeks since the patient's stroke onset. CIAT sessions (1st TP) will be three-hour long and delivered on a daily basis (also 5 days per week) for two weeks, resulting in a total of 30 hours of therapy. CIAT sessions (2nd TP) will be three-hour long and delivered on a daily basis (also 5 days per week) for two weeks, resulting in a total of 30 hours of therapy.

Primary outcomes

1. Conversational speech

   From The Cookie Theft picture description of the Boston Diagnostic Aphasia Examination (BDAE)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

2. Repetition

   From the Word and sentence repetition test of the Boston Diagnostic Aphasia Examination (BDAE)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

3. Naming (auditory confrontation)

   From the Responsive naming test of the Boston Diagnostic Aphasia Examination (BDAE)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

4. Naming (visual confrontation)

   From the Boston Naming Test of the Boston Diagnostic Aphasia Examination (BDAE)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

5. Verbal fluency

   From the Verbal Fluency Test (VFT)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

6. Functional communication

   From the Communicative Activity Log (CAL)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

Secondary outcomes

1. Auditive comprehension

   From the Commands test of the Boston Diagnostic Aphasia Examination (BDAE)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

2. Depression

   From the Signs of Depression Scale (SODS) and Stroke Aphasia Depression Questionnaire (SADQ-10)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

3. Lesion volume and extent

   By MRI Voxel-based Lesion-Symptom Mapping (VLSM)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

4. White matter integrity

   By MRI Diffusion Weighted Imaging (DWI)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)

5. Neurofunctional activation

   By Resting-State Functional MRI (rs-fMRI)

   Time frame: At baseline (day 63), after 1st therapeutic period (day 106), before 2nd therapeutic period (day 182) and after 2nd therapeutic period (day 225)